Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts.

Autor:	Gonzalez Dias Carvalho PC; Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Dominguez Crespo Hirata T; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil., Mano Alves LY; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil., Moscardini IF; Microbiotec Srl, Siena, Italy., do Nascimento APB; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Costa-Martins AG; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.; Artificial Intelligence and Analytics Department, Institute for Technological Research, São Paulo, Brazil., Sorgi S; Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Department of Medical Biotechnologies, University of Siena, Siena, Italy., Harandi AM; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada., Ferreira DM; Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Vianello E; Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Haks MC; Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Ottenhoff THM; Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands., Santoro F; Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Department of Medical Biotechnologies, University of Siena, Siena, Italy., Martinez-Murillo P; Centre for Vaccinology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Huttner A; Centre for Vaccinology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Infectious Diseases Service, Geneva University Hospitals, Geneva, Switzerland., Siegrist CA; Centre for Vaccinology, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Medaglini D; Department of Medical Biotechnologies, University of Siena, Siena, Italy., Nakaya HI; Scientific Platform Pasteur-University of São Paulo, São Paulo, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Nov 08; Vol. 14, pp. 1259197. Date of Electronic Publication: 2023 Nov 08 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1259197
Abstrakt:	Introduction: The rVSVDG-ZEBOV-GP (Ervebo®) vaccine is both immunogenic and protective against Ebola. However, the vaccine can cause a broad range of transient adverse reactions, from headache to arthritis. Identifying baseline reactogenicity signatures can advance personalized vaccinology and increase our understanding of the molecular factors associated with such adverse events. Methods: In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination. Results and Discussion: We analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach revealed 22 key genes associated with adverse events such as local reactions, fatigue, headache, myalgia, fever, chills, arthralgia, nausea, and arthritis, providing insights into potential biological mechanisms linked to vaccine reactogenicity. Competing Interests: Author IM was employed by the company Microbiotec Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2023 Gonzalez Dias Carvalho, Dominguez Crespo Hirata, Mano Alves, Moscardini, do Nascimento, Costa-Martins, Sorgi, Harandi, Ferreira, Vianello, Haks, Ottenhoff, Santoro, Martinez-Murillo, Huttner, Siegrist, Medaglini and Nakaya.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu